Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004190 · ClinicalTrials.gov registry record · Phase 2

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer

A Phase 2 study of Pancreatic Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
59
Enrollment target
19
Study locations

NCT00004190 is a Phase 2 study of Pancreatic Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 59 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (85% lower). The trial reports 19 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004190, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
59 participants
Enrollment target
19
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and oxaliplatin in treating patients who have refractory locally advanced or metastatic pancreatic cancer.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG oxaliplatin
  • DRUG gemcitabine hydrochloride

Study Locations (19)

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • CentraCare Clinic - Saint Cloud

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria
  • CCOP - Carle Cancer Center - Urbana

North Dakota

  • Quain & Ramstad Clinic, P.C. - Bismarck
  • CCOP - Merit Care Hospital - Fargo

South Dakota

  • Rapid City Regional Hospital - Rapid City
  • CCOP - Sioux Community Cancer Consortium - Sioux Falls

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale

Kansas

  • CCOP - Wichita - Wichita

Michigan

  • CCOP - Ann Arbor Regional - Ann Arbor

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 1999-10
Est. Completion 2003-06
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00004190

The ClinicalTrials.gov registry entry for NCT00004190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which oxaliplatin is the first listed.

NCT00004190 reports 19 study locations spanning 12 distinct geographic areas - top geographies include Iowa, Minnesota, Illinois.

Frequently Asked Questions

What is clinical trial NCT00004190 about?

NCT00004190 is a clinical study titled "Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and oxaliplatin in treating patients who have r...

What is the current status of trial NCT00004190?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 1999-10. Estimated completion is 2003-06.

What conditions does trial NCT00004190 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT00004190?

The interventions under investigation include: oxaliplatin (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00004190?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004190 being conducted?

This trial has 19 study locations across Arizona, Illinois, Iowa, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.